



Bal Pharma Limited

To,
The Manager-Listing
BSE Limited
Mumbai.

25.09.2024

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Brief Proceedings of 37th Annual General Meeting ('AGM') held on 25.9.2024.

Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 37th Annual General Meeting of the Company conducted through audio visual means, on 25.09.2024.

Mr. Shailesh Siroya was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum and transacted the following business.

Ordinary Business:

1. Received, considered and adopted the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2024, the Statement of Profit and Loss for the financial year ended as on that date and the Cash Flow Statement together with the Reports of the Board of Directors and the Auditors thereon.
2. Declared dividend of Re.1.20/- per Equity Share of Rs.10/- each.
3. Appointed Mr. Kotian Chittanand Damodar (DIN # 09613054), Whole Time Director of the Company, who was retiring by rotation and being eligible, offered himself for reappointment.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820





Bal Pharma Limited

Page-2

Special Business:

4. Re-appointed Mr.Himesh Virupakshya (DIN # 08554422) as Whole time Director of the Company and fixed his remuneration for the next 3 years.
5. Re-appointed Mr.Shailesh Siroya (DIN # 00048109) as Managing Director of the Company and fixed his remuneration for the next 3 years.
6. Approved reclassification of the promoter group.
7. Ratified the remuneration payable to the Cost auditors for the financial year 2023.24.

Chairman provided a brief overview on the performance of the Company during the financial year 2023.24 and later invited questions and/or clarifications from the members attending the meeting through audio visual means. Queries from the shareholders received through e-mail were also answered suitably by the Chairman.

Mr.Prameshwar G Bhat, practising Company Secretary was appointed as the scrutinizer for the e-voting and the results of e-voting will be announced after receipt of Scrutinizer's Report.

The e-voting results will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also uploaded on our website.

The 37th Annual General Meeting commenced at 11.30 AM as scheduled and concluded at 12.10 PM on 25.09.2024.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited


Shailesh Siroya
Managing Director.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820